They Did Not Think I Was Able To Develop Into A Sunitinib Guru...Nowadays I Am !

3 patients developed ARD pre-operatively and 24 post-operatively. The demographics of patients with acute renal dysfunction (ARD group) and those without acute renal dysfunction (non-ARD group) are shown in Table 2. The ARD group were older, had significantly more Temozolomide medical co-morbidities and were receiving greater numbers of nephrotoxic medications, compared to the non-ARD group. 1 in 3 men with a hip fracture developed ARD. Inpatient mortality within the ARD group was 5/27 patients (19%) and there were no inpatient deaths in the non-ARD group. Of the 22/27 patients who survived, renal function had improved, with the median eGFR closer to normal (60?ml/min/1.73?m2) by the date of discharge. The 30-day mortality was 22% (6/27 patients) in the ARD group, compared Sunitinib in vitro to 4% (5/143 patients) in the non-ARD group. The 120-day mortality was 41% (11/27 patients) in the ARD group compared to 13% (19/143 patients) in the non-ARD group. There was a significant difference between the length of time from admission to surgery between groups; 48% of patients in the ARD group had their surgery within 2 days compared to 70% in the non-ARD group (p?Levetiracetam 63?ml/min/1.73?m2, interquartile range 53�C76?ml/min/1.73?m2) (p?